Please login to the form below
Horizon Therapeutics
This page shows the latest Horizon Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Amgen announces plans to acquire Horizon for $27.8bn in biggest pharma deal for 2022
The acquisition will see Amgen pay $116.50 for each Horizon share in cash. ... Amgen has announced its plans to acquire biopharmaceutical company, Horizon Therapeutics (Horizon), in a deal worth approximately $27.8bn, making it the biggest pharma buyout
Latest news
-
Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition
Viela's portfolio of assets includes FDA-approved NMOSD therapy Uplizna. Horizon Therapeutics has entered into a definitive agreement to acquire Viela Bio for $3bn, in an effort to strengthen its ... In January 2020, Horizon received FDA approval for its
-
Sanofi Genzyme takes home New Product Introductions Award at PMEA 2020
With support from Lucid Group, Sanofi Genzyme’s ‘A Licensed Systemic Therapy for Advanced Cutaneous Squamous-Cell Carcinoma’ saw off competition from Takeda and Horizon Therapeutics to take home this award.
-
FDA approves Horizon's thyroid eye disease drug ahead of schedule
First FDA-approved treatment for rare autoimmune condition. Horizon Therapeutics has won a speedy approval for its thyroid eye disease (TED) treatment Tepezza in the US. ... Having secured the FDA approval, Horizon will now turn its attention to making a
-
Allergan buys two NASH drug developers in one day
Other candidates in clinical development include Bristol-Myers Squibb/Ambrx' BMS 986036, Horizon/Raptor Therapeutics' RP103, Zydus Cadila's saroglitazar (in phase III) and Gilead Sciences' simtuzumab (phase II). ... The two deals take Allergan's
-
CHMP recommends 19 new medicines for European approval
and Horizon Therapeutics' Ravicti (glycerol phenylbutyrate) which is used for urea cycle disorders.
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
Another of its partners, Horizon Therapeutics recently submitted to the FDA the Genmab-developed teprotumumab for the treatment of active thyroid eye disease.
-
Deal Watch table for March 2014
Vidara Therapeutics/. Horizon Pharma. Merger/ acquisition. Actimmune (interferon gamma-1b) for CGD and SMO (approved). ... 660. Five Prime Therapeutics/ BMS. Collaboration, licence. Drug discovery against two undisclosed targets in immune checkpoint
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Ziarco appoints Mike Grey to board of directors
Grey is currently on the boards of BioMarin Pharma, Horizon Pharma, Mirati Therapeutics and Selventa.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Creabilis names Catherine Moukheibir as chairman of the board
- World Health Organization releases latest set of COVID-19 guidelines
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
